H.C. Wainwright reiterates Aclaris stock rating after trial miss
H.C. Wainwright reiterated a Buy rating and $16.00 price target on Aclaris Therapeutics (ACRS) despite its Phase 2 trial for bosakitug missing primary and secondary endpoints. The stock fell 8% to $3.60 post-announcement. Analysts remain bullish on ACRS's broader pipeline, with a Strong Buy consensus and price targets ranging from $4 to $16.
How this was made
The 30-second read
Why it matters
The clinical miss is the immediate driver for sentiment, while the analyst framing shifts focus away from standalone bosakitug and toward the ATI-052 flagship candidate.
Market read
Traders get a near-term catalyst mix: a Phase 2 efficacy miss driving the selloff, plus a reiterated Buy that may limit downside if investors keep faith in the remaining pipeline.
What to watch
The article mentions robust target engagement and tolerability, which could support subgroup or combination strategies, but it does not specify any next-step plan or timeline.
Background
H.C. Wainwright reiterates a Buy rating and $16 price target after Aclaris reported Phase 2 ADMIRATION top-line results for bosakitug in atopic dermatitis.
Ticker impact
Aclaris shares fell after Phase 2 ADMIRATION results for bosakitug missed endpoints, prompting H.C. Wainwright to reiterate Buy and a $16 target.
Likely continued volatility and downside bias as investors weigh the clinical miss against the unchanged pipeline thesis.
The article centers on a Phase 2 miss and a sell-side stance split, with the reiterated Buy relying on the remaining flagship program rather than the failed asset.
Market effects
Reinforces risk-off sentiment for atopic dermatitis monoclonal antibody approaches after a Phase 2 miss, while keeping attention on alternative modalities in the same pipeline.
Limited, single-name biotech catalyst with no broader macro linkage.
Primarily US biotech sentiment; no direct global policy or cross-market linkage described.
Counterpoint
The reiterated Buy may be underweighting the probability that ATI-052 faces similar efficacy risk, given the trial’s biomarker engagement did not translate into endpoint success.
Key entities
- companyAclaris Therapeutics
NASDAQ-listed biotech whose Phase 2 ADMIRATION trial for bosakitug missed endpoints; stock fell and sell-side views diverged.
- drug_candidatebosakitug (ATI-045)
Humanized anti-TSLP monoclonal antibody evaluated in Phase 2 ADMIRATION for atopic dermatitis.
- drug_candidateATI-052
Bispecific construct viewed by H.C. Wainwright as the flagship candidate in Aclaris’s portfolio.
- analyst_firmH.C. Wainwright
Reiterated Buy rating and $16 price target after the Phase 2 trial results.
- analyst_firmWedbush
Downgraded to Neutral and cut price target to $3 after the Phase 2 setback.

